Journal article
Exploratory analysis of glyburide as a novel therapy for preventing brain swelling
KN Sheth, W Taylor Kimberly, JJ Elm, TA Kent, AJ Yoo, G Thomalla, B Campbell, GA Donnan, SM Davis, GW Albers, S Jacobson, G Del Zoppo, J Marc Simard, BJ Stern, P Mandava
Neurocritical Care | HUMANA PRESS INC | Published : 2014
Abstract
Background: Malignant infarction is characterized by the formation of cerebral edema, and medical treatment is limited. Preclinical data suggest that glyburide, an inhibitor of SUR1-TRPM4, is effective in preventing edema. We previously reported feasibility of the GAMES-Pilot study, a two-center prospective, open label, phase IIa trial of 10 subjects at high risk for malignant infarction based on diffusion weighted imaging (DWI) threshold of 82 cm3 treated with RP-1127 (glyburide for injection). In this secondary analysis, we tested the hypothesis that RP-1127 may be efficacious in preventing poor outcome when compared to controls. Methods: Controls suffering large hemispheric infarction wer..
View full abstractGrants
Awarded by National Institute of Neurological Disorders and Stroke
Funding Acknowledgements
The sponsor for this study was Remedy Pharmaceuticals, Inc.